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1 Administrative information 
Title: Sub-acromial spacer for Tears Affecting Rotator cuff Tendons: a Randomised, Efficient, 
Adaptive Clinical Trial in Surgery (START:REACTS). 
Trial registration number: ISRCTN17825590 








Details of SAP changes 
Date of 
update 
0.1-0.2 3 - Working drafts - 
0.3 4 - 
Working draft updated to reflect v4 of 
protocol 
24/09/19 
0.4 4 - 
Working draft to circulate to TMG, inclusion 
of suggestions from Sept 19 DMC meeting. 
Change of junior statistician 
31/10/19 
1 4 6; 8 
Addition of unbiased treatment estimated to 
planned analysis. Clarification of WORC 
scoring. Update to dummy tables. Updated 
NIHR logo. 
20/02/20 
1.1 5 2.3; 3.3; 6 
Response to covid-19 epidemic: change of 






Analysis finalised prior to the final primary 
outcome data collected. Edits to text for 




1.2 Supporting documents 
This Statistical Analysis Plan (SAP) should be read in conjunction with the study protocol and WCTU 
Standard Operating Procedures: 
 SOP 8: Statistical Considerations 
 SOP 9: Randomisation and Blinding 
 SOP 15: Information Handling 
 SOP 21: Statistical Analysis Plan 
Details on the adaptive design element of the study are included in the START:REACTS adaptive 
charter. 
The Trial Master File, including the Data management Plan can be found in the START Trial 
Manager’s office. 
1.3 Study oversight 
As described in the protocol, the procedures in place for oversight of this study include both a Trial 
Steering Committee (TSC) and Data Monitoring Committee (DMC). The DMC is advisory to the TSC 
and write to the TSC and recommend any alterations to the study to ensure the safety of 
participants and the integrity of the data. 
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1.4 Key roles and responsibilities 
Details of all other START:REACTS co-applicants can be found in the protocol. 
Role  Name, address, telephone, email 
Chief Investigator Mr Andrew Metcalfe 
Warwick Clinical Trials Unit 





Dr Helen Parsons  
Senior Research Fellow, Warwick Clinical Trials Unit 
Tel: 02476 572665 
Email: H.Parsons@warwick.ac.uk 
 
Junior Statistician Aminul Haque; Research Assistant 
Warwick Clinical Trials Unit 





Dr Nicholas Parsons (Adaptive methodology) 
Principal Research Fellow, Warwick Medical School 
Email: nick.parsons@warwick.ac.uk 
 
Professor Nigel Stallard (Adaptive methodology) 
Professor of Medical Statistics & Epidemiology, Warwick Medical School 




START REACTS Trial Manager 
Warwick Clinical Trials Unit, Clinical Sciences Building, Clinical Sciences 
Research Laboratories, University Hospitals Coventry and Warwickshire, 
Clifford Bridge Road, Coventry, CV2 2DX  





Omitted for WRAP upload 
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1.5 Signatures  
Signatures may also be found on QPulse 
Role Name Date Signature 
Author of SAP    
Senior statistician (if 
different to author) 
   
Chief Investigator    
2 Introduction and summary of protocol 
2.1 Trial background and rationale 
Shoulder pain is a common and disabling problem, with around 70-80% of problems due to rotator 
cuff disease. Patients with a symptomatic rotator cuff tear present with pain, restricted movement, 
loss of strength and disability, and the disease is associated with substantial expense to society 
through both costs of treatment and sick leave. Rotator cuff repair is a widely accepted treatment 
for symptomatic rotator cuff tears. However, some tears cannot be repaired (“irreparable tears”) 
and the management of these patients can be very difficult. Arthroscopic debridement is commonly 
used and benefit has been demonstrated in case-series, but it remains a controversial option, with 
little or no benefit observed in randomised trials.  
In 2013, the InSpace subacromial device (Stryker) was introduced into UK orthopaedic practice as a 
potential treatment option for people with irreparable tears of the rotator cuff. The InSpace device 
is a saline-filled, balloon made of biodegradable (dissolvable) synthetic material. It is inserted above 
the main joint of the shoulder at the end of an arthroscopic debridement after an irreparable tear 
has been identified. It is simple to deploy and adds less than 10 minutes to the operation. In May 
2016, an interventional procedure guidance document was published by NICE, five years following 
its use in clinical practice, demonstrating very limited evidence for its use. Therefore, the device was 
limited to use in the context of research only and a research recommendation was made to assess 
its effectiveness.  
More details on the background to the trial can be found in the protocol. 
 
2.2 Interventions 
A brief description of each trial intervention is provided below, full descriptions can be found in the 
protocol. 
2.2.1 Control group: arthroscopic debridement alone 
After being established as eligible at surgery (see section 5.2), the control group will receive 
arthroscopic debridement (surgery) only. 
2.2.2 Intervention group: arthroscopic debridement with InSpace device 
The intervention group will receive arthroscopic debridement as in the control group, with the 
additional insertion of the InSpace device during the surgery. 
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2.3 Trial aims and objectives 
The overarching aim is to implement a novel, efficient adaptive clinical trial design for new surgical 
interventions. This design will be used to assess the clinical effectiveness and safety of a sub-
acromial spacer device for patients with symptomatic irreparable tears of the rotator cuff. 
2.3.1 Protocol changes due to the covid-19 pandemic in 2020  
The trial was planned and powered using the Constant shoulder score (CS). However, the covid-19 
pandemic, which reached the UK in March 2020, required the study management team to make a 
number of urgent changes to the study protocol. This ensured that the trial could continue to recruit 
participants and collect follow-up data safely as study population includes many who are categorised 
as extremely clinically vulnerable to covid-19. Chiefly amongst these changes was the decision to 
make the Oxford shoulder score (OSS) at twelve months after surgery the primary study outcome. 
The OSS can be completed remotely (e.g. by telephone), in contrast to the CS which requires in 
person contact with patients. The decision to change the primary outcome was made by the trial 
management group, and agreed by the independent data monitoring committee and the trial 
steering committee on the 25th of March and the 7th of July 2020 respectively. 
2.3.2 Primary objective 
To quantify and draw inferences on observed differences between arthroscopic debridement of the 
subacromial space and arthroscopic debridement with insertion of the InSpace device twelve 
months after surgery, using the Oxford Shoulder Score (OSS) score.  
2.3.3 Secondary objectives 
The following secondary objectives are covered in this SAP. Other secondary objectives are outlined 
in the protocol. 
1) To quantify and draw inferences on observed differences between the allocation groups at 
each follow up time point for the following outcomes: 
i. The Oxford Shoulder Score (OSS) at all other time points other than at 12 months  
ii. The Constant score and the Western Ontario Rotator Cuff index (WORC)  
iii. Shoulder pain free movement and strength 
iv. EQ5D 
v. Patient global impression of change (PGIC)  
2) To assess the proposed mechanism of action of the device when it is still inflated and to 
determine if the effect persists when it has deflated (MRI substudy). 
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3 Study methods 
3.1 Trial design 
This study is a UK multi-centre, adaptive randomised controlled trial of two parallel treatment arms 
with an allocation ratio of 1:1. 
The trial uses a novel adaptive study design. Further information on the adaptive element of the trial 
and details on how this will be carried out is described in the adaptive charter. 
3.2 Randomisation 
Participants will be randomly allocated (1:1) to the two treatment groups via a central computer-
based randomisation system provided by the Warwick Clinical Trials Unit (WCTU, independent of the 
study team). This will be performed by minimisation with a random factor, with a 70% weighting 
towards balance across the whole study, using site, gender, age group (<70 years and ≥70 years, 
based on age distribution of previous studies) and cuff tear size ( ≥3cm or <3cm, measured intra-
operatively) as strata. 
3.3 Sample size 
Initially, the study was designed using the Constant score. For the Constant score at twelve months, 
a clinically important difference of 10 units was selected along with a standard deviation of 20 and a 
standardised mean difference of 0.5. A magnitude of 0.5 is expected for the correlations between 
the Constant scores at three, six and twelve months.  
For the Oxford Shoulder Score, anchor-based studies have estimated the target difference as 6 and a 
standard deviation of 12 has been observed in multiple studies, [1] therefore, a moderate 
standardised mean difference of 0.5 remains appropriate. An assumed correlation of 0.5 between 
time-points remains appropriate based on data from previous studies in our unit in a similar 
population. [2] 
Hence, for a study without early stopping, at 5% significance and 90% power would require 170 
participants without loss any loss to follow up. 
The adaptive design used for this study allows stopping for either efficacy (arthroscopic debridement 
with the InSpace device performs better than arthroscopic debridement alone) or futility (the device 
performs no better than arthroscopic debridement alone) at a number of pre-specified interim 
analyses (early looks). [3] The timing of the early looks will be determined by the information 
accrued during participant follow-up. The information is dependent on the variance of the 3, 6 and 
12 month OSS, and the correlation between the scores, in addition to the numbers and pattern of 
data accrual (i.e. the relative and absolute numbers of 3, 6 and 12 month scores). Using the best 
available knowledge of the pattern and timings of data accrual, with estimates of the variances and 
correlations from the research literature, simulations were undertaken to assess the likely sample 
size required to detect a clinically important difference in 12 month OSS.  
The simulations tested a range of options for the number of interim looks and the type I error rate 
spent; for examples of simulations see Parsons et al. [3] In order to preserve the integrity of the trial 
the details of the selected design will remain confidential and known to the relevant members of the 
methodology TMG and DMC only; full details are in the adaptive charter. For the selected design, 
simulations indicate that a sample size of 188 participants would be required for a power of 90% at 
the 5% significance level. A total sample size of 221 participants is then needed to allow for a loss to 
follow up rate of 15%. 
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3.4 Framework 
The objectives in this trial SAP will be tested using a frequentist superiority hypothesis testing 
framework. 
3.5 Blinding 
The participants and assessors in the trial will be blinded to the allocation group. With the exception 
of the trial statisticians, blinding of the TMG members will be maintained where possible 
3.6 Interim analyses and stopping guidance 
Sequential stopping boundaries will be constructed that allow stopping for futility or stopping to 
reject the null hypothesis (efficacy), with interim analyses predefined and agreed with the TSC and 
DMC. Further information on the stopping rules and how they will be implemented is given in the 
adaptive charter. 
The DMC and TSC retain their rights to stop the study for other reasons at any time.  
3.7 Timing of final analysis 
The final analysis will be carried out once the last 12 month outcome data have been collected.  
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3.8 Timing of outcome assessments 





(No. weeks  weeks (w) 
/months (m))  
Screening Baseline Surgery 
8 weeks (-2 w/ 
+4 w) after V2 
3m (-2 w/+6w) 
after V2 
≥6 m 
(6 w) After V2 




Check eligibility and 
provide PIS 
        
Check inclusion and 
exclusion criteria  
        
Consent (and sub-study 
consent) 
        
Baseline assessments         
Randomisation         
Intervention         
Constant Score       *  
PROMs         
Resource use         
Adverse Events         
Sub-study MRI         
End of trial         
*primary outcome time point 
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4 Statistical principles 
4.1 Confidence intervals and P values 
All data will be analysed and reported in accordance with the CONSORT statement and its extension 
for adaptive designs. [4, 5] Treatment effects will be presented, with appropriate 95% confidence 
intervals, for both the unadjusted and adjusted analyses. Tests will be two-sided and considered to 
provide evidence for a significant difference if p-values are less than 0.05 (5% significance level) 
unless otherwise stated. 
4.2 Descriptive statistics 
Standard descriptive summaries will be provided for the primary outcome measure (OSS) and all 
secondary outcome measures. Baseline data will be summarised to check comparability between 
treatment arms.  
4.3 Adherence and protocol deviations 
The delivery of the trial interventions will be recorded on a surgical case report form (CRF) which will 
be used to determine if the participant adhered to the treatment for analysis purposes. 
Protocol deviations will be categorised into groups as appropriate after consultation with the Trial 
Management Group (TMG). 
4.4 Analysis populations 
All analyses will be conducted as intention to treat unless otherwise specified (e.g. any per protocol 
analyses as sensitivity analyses). 
5 Trial populations 
5.1 Screening data 
Screening data will be checked to highlight the proportion of patients approached who agreed to 
participate in the study and observe the reasons why potential participants were not included 
participation in the trial. 
5.2 Eligibility 
5.2.1 Inclusion criteria 
1. Rotator cuff tear deemed by the treating clinician to be technically irreparable (to be 
confirmed intra-operatively) 
2. Intrusive symptoms (pain and loss of function) which in the opinion of the treating clinician 
warrants surgery.  
3. Non-operative management has been unsuccessful.  
5.2.2 Exclusion criteria 
4. Advanced gleno-humeral osteoarthritis on pre-operative imaging. 
5. Subscapularis deficiency, defined as a tear involving more than the superior 1cm 
(approximately) of the subscapularis if repaired, or any tear that is not repaired.  
6. The treating clinician determines that interposition grafting or tendon transfers are indicated.  
7. Pseudoparalysis as determined by the treating clinician. 
8. Unrelated, symptomatic ipsilateral shoulder disorder that would interfere with strength 
measurement or ability to perform rehabilitation 
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9. Other neurological or muscular condition that would interfere with strength measurement or 
ability to perform rehabilitation. 
10. Previous proximal humerus fracture that could influence shoulder function. 
11. Previous entry into the present trial (i.e. other shoulder). 
12. Unable to complete trial procedures. 
13. Age under 18  
14. Unable to consent to the trial. 
15. Unfit for surgery. 
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5.3 Recruitment 
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5.4 Withdrawal and loss to follow up 
The following levels of withdrawal are possible in the study: 
 Withdrawal from registration: these participants are not formally considered part of the 
study as they have withdrawn prior to being allocated a treatment 
 Partial withdrawal from follow up: the participant withdraws from in-person follow up. 
However, the participant will be retained in the study and asked to complete postal 
questionnaires containing secondary outcomes 
 Total withdrawal from the study: the participant withdraws from all follow up (in person and 
via post) 
Due to the nature of the study design, withdrawal from the intervention is not possible. Data from 
withdrawn participants will be retained and used in analyses unless otherwise requested by the 
participant. 
5.5 Baseline patient characteristics 
Baseline data including age, sex, BMI, site and cuff tear size will be summarised to check 
comparability between treatment arms. Further details can be found in the Table 6, Table 7 and 
Table 8. 
6 Analysis 
6.1 Patient reported outcome definitions 
The patient reported outcomes used in the trial are defined below: 
Oxford Shoulder Score (OSS): A patient reported outcome measure consisting of 12 items designed 
to assess the outcomes of shoulder surgery. The OSS is measured on a scale of 0-48 where 48 is the 
best possible outcome. The OSS will be assessed as the primary clinical outcome at 12 months, along 
with three and six month data that will also be collected. The score will be calculated as described by 
the OSS scoring system. [6] 
Constant-Murley score (Constant score): An outcome measure designed to indicate the overall 
functionality of patients with a shoulder disorder, measured on a scale of 0-100 with higher numbers 
representing better functionality. The Constant score consists of four parts, pain, activities of daily 
living, movement and strength and will be calculated as described in the Ban et al paper [7]. This 
outcome will be collected as a secondary outcome. 
Western Ontario Rotator Cuff index (WORC): A patient reported quality of life outcome measure 
designed for patients with rotator cuff disease and consisting of 21 questions. Each question in the 
WORC is answered in the format of an 11 point numerical rating scale (NRS), which is converted into 
a total percentage score, with higher percentages indicating worse symptoms. Subscales are 
described in the WORC user manual. [8] 
EQ-5D: Is a validated, generic health-related quality of life measure consisting of five items each with 
five possible responses. These are then converted into a health utility score using the UK value set as 
recommended by the Health Economic Team (e.g. [9]). Both the statistical and health economic 
analyses will use the same utility values to ensure compatibility. 
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6.2 Analysis of efficacy 
Standard statistical summaries (e.g. medians and ranges or means and variances, dependent on the 
distribution of the outcome) and graphical plots showing correlations will be presented for the 
primary outcome measure and all secondary outcome measures. Outcome measure data, such as 
the OSS and Constant scores, will be assumed to be normally distributed during modelling, but 
subsidiary analyses may also be undertaken after appropriate variance-stabilising transformation if 
assumptions of normality prove to be unsustainable. 
6.2.1 Primary clinical analysis 
The primary analysis will follow the methods and use the test statistic described by Parsons et al. [3] 
The test statistic at the end of the study (after follow-up is complete) is given by the expression 
𝐵 𝑠𝑑(𝐵)⁄ , where 𝐵 is a measure of the treatment effect of the device arm versus the arthroscopic 
debridement alone arm; expressions for estimating 𝐵 and 𝑠𝑑(𝐵) (the standard deviation of the 
effect estimate) are given by equations (1) and (2) of Parsons et al. [3] . Unbiased estimates of the 
treatment effect (B) will be determined using the methods of Liu and Hall [10], with confidence 
intervals estimated using the approach of Todd, Whitehead and Facey [11]. These unbiased 
estimates will be reported as the primary analysis and will be used for inferences on clinical 
significance. 
If the study recruits to target, without stopping at an interim analysis, then testing at the final 
analysis (at the end of 12 month follow-up) will use the pre-specified adjusted boundaries from the 
adaptive charter. If the test statistic is greater than the upper boundary, then the null hypothesis will 
be rejected at the 5% level. If the study is stopped at an interim analysis, then the final ‘overrunning’ 
analysis will use data from all the participants recruited into the study prior to stopping. In this 
setting, testing will proceed using boundaries calculated by the deletion method of Whitehead [12], 
with inferences as per the unstopped analysis (i.e. rejection of the null hypothesis at the 5% level if 
the test statistic is greater than the upper boundary). If recruitment proves to be problematic, or for 
some unforeseen reason one or more than one (or all) interim analyses do not take place, then 
testing will proceed in a similar manner using boundaries adjusted to reflect the changes to the 
design. 
In addition to reporting the statistical significance of the tests, treatment effect estimates 
(arthroscopic debridement with InSpace device versus arthroscopic debridement alone) from the 
primary analysis will be presented with 95% confidence intervals, and a statement of the clinical 
significance of reported differences. 
 
6.2.2 Secondary clinical analysis 
Summary plots will be used to show both the distributions (e.g. box-and-whisker plots) and temporal 
trends in intervention arm means for all outcomes (Constant, OSS, EQ-5D and WORC) at 3, 6, 12 and 
24 months. Treatment effect estimates (arthroscopic debridement with InSpace device versus 
arthroscopic debridement alone) will be presented with 95% confidence intervals.    
The results of the primary clinical analysis will be augmented with the results of fitting a mixed-
effects model to the primary OSS and secondary outcomes (Constant score , EQ-5D and WORC) at 12 
months, adjusting for the fixed-effects of baseline score, age group (70 years and ≥70 years), gender 
and cuff tear size (≥3cm or <3cm), with the inclusion of a random recruiting centre effect. Variables 
found to be imbalanced at baseline may also be included. Since individual clinicians will treat only a 
small number of patients enrolled in the trial, we do not expect clinician specific effects to be 
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important in this study and hence these will not be modelled. Inferences, regarding the effects of 
the arthroscopic debridement with InSpace device versus the arthroscopic debridement alone, will 
be made using the conventional (fixed design) boundaries, with significance assessed at the 5% level. 
If the study is stopped early at an interim analysis (or otherwise), collinearity between key variables 
may be observed. For example, sites with a small number of randomisations may not have sufficient 
participants to use all strata groups. If this occurs, variables may be omitted or transformed where 
possible (e.g. replace age group with age at baseline). If study site is the variable causing the 
difficulties, a fixed effect model may be used instead. Similarly, if any pre-planned model variables 
(e.g. baseline OSS) are poorly reported such that it reduces the available sample size for the analysis, 
then they will not be included in the definitive model. 
Complications will be summarised with between groups comparisons evaluated using chi-squared or 
Fisher’s exact tests. If a large number of participants are observed not to confirm with the protocol, 
a per-protocol sensitivity analysis will also be constructed. If more extensive analysis of 
complications is deemed appropriate (i.e. they are sufficiently common to make more complex 
analysis useful), then mixed-effects logistic regression models (analogous to those described above) 
will also be fitted. 
Other outcomes will be summarised and compared between groups using appropriate tests for the 
outcome (e.g. proportions and chi-squared tests for binary outcomes, means and t-tests for 
continuous data). 
 
6.3 Missing data 
It seems likely that some data may not be available due to voluntary withdrawal of patients, lack of 
completion of individual data items or general loss to follow-up. Where possible the reasons for data 
‘missingness’ will be ascertained and reported. Reasons for ineligibility, non-compliance, withdrawal 
or other protocol violations will be stated and any patterns summarised. 
The nature and pattern of the missingness will be carefully considered, including whether data can 
be treated as missing completely at random (MCAR). Variables that will be checked for their impact 
on missingness rates will include: site, gender, age group and cuff tear size. If judged appropriate, 
missing data will be imputed using multiple imputation. Any imputed analyses will be considered as 
secondary analyses and will be reported along with the primary analysis. 
If imputation is undertaken, the resulting imputed datasets will be reported, together with 
appropriate sensitivity analyses. Any imputation methods used for scores and other derived 
variables will be carefully considered and justified. In particular, the model used for the multiple 
imputation will be assessed along with the plausibility of any imputed values.  
 
6.4 Additional Analyses 
6.4.1 Sensitivity analyses 
Due to the nature of the study, it is not anticipated that there will be many participant cross-overs 
between allocation groups and/or protocol violations. However, if a sizable number of cross-overs 
are observed, a per-protocol analysis will be conducted as a sensitivity analysis. This analysis will 
follow the method set out above (section 6.2.1), but grouped as treatment received rather than as 
treatment allocated. 
   
 




Pre-specified sub-group analyses will be undertaken to assess whether there is evidence that the 
intervention effect differs between:  
• The size of the rotator cuff tear as measured at the start of surgery, defined as large or massive 
cuff tear (≥3cm) or moderate to small (<3cm). 
• Gender 
• Age (>70 or <70) 
The subgroup analyses will follow the methods described for the secondary clinical analysis, with 
additional interaction terms incorporated into the mixed-effects regression model to assess the level 
of support for these hypotheses.  
The study is not powered to formally test these hypotheses, so they will be reported as analyses 
only, and as subsidiary to the analysis reporting the main effects of the intervention in the full study 
population. 
 
6.4.3 Repairable cuff tears 
Due to the larger than anticipated number of potential participants excluded intra-operatively due 
to their cuff tears being found to be repairable, an exploratory analysis comparing the baseline 
outcome scores of the reparable and irreparable (randomised) patients will be conducted.  
Descriptive statistics of the two tear types will be conducted of the baseline information. Direct 
comparisons between tear types will be assessed using a t-test for the baseline OSS. If deemed 
informative, as this population is not randomised, regression analyses to adjust for any imbalance 
between patient age group (<70 years and ≥70) and patient gender will also be carried out.  
 
6.4.4 Effect of covid-19 
In March 2020, the UK went into “lockdown” as a response to the covid-19 epidemic. The NHS 
reduced or stopped routine appointments and elective surgery. As the use of the device is thought 
to help patients engage with rehabilitation more quickly and successfully, the cancellation or 
reduction of post-surgery physiotherapy may impact on the recovery of participants during this time.  
Hence, outcome data collected before and after the lockdown started will be compared. The 
number of missing primary outcome scores will be reported along with the number of patient 
reported physiotherapy contacts. Recovery trajectories will be presented graphically to help aid 
interpretation.   
 
6.5 MRI sub-study 
The aim of the sub-study is to assess the mechanism of action of the InSpace device. Measurements 
will be taken at two time points: an “early” time point when the devices are likely to be still inflated 
approximately 8 weeks post-randomisation (when acute post-operative pain has subsided); and a 
“later” time point, when the devices are likely to have fully deflated at least six months post-
randomisation to see if the proposed mechanism for ongoing improvement is maintained. 
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6.5.1 Sub-study sample size 
Based on Gumina’s study [13], the minimum acromio-humeral distance (AHD) has a standard 
deviation of 1.72mm, so to observe a minimum important difference of 1.5mm (above the minimum 
detectable change of 1.3mm) 80% power at the 5% level, 44 participants (two groups of 22 
participants) are required. Assuming a conservative loss to follow-up rate at six months of 20%, 56 
participants are required for this sub-study.  
6.5.2 Sub-study outcomes 
The primary outcome will be the minimum acromio-humeral distance (AHD, as defined by Gumina) 
on the ‘deltoid-active’ coronal sequences at six months.  
Secondary measures will be AHD at the first MRI; AHD on passive and sagittal images, and the 
change in AHD between active and passive images. The position of the device will be assessed on 
both sequences (with particular focus on the sagittal images) to check for migration and consistency 
of placement relative to the acromion. 
6.5.3 Sub-study analyses 
The primary end-point will be the between group difference on the later MRI, as that is the better 
indicator of long-term function and will determine whether the early effect of the device is likely to 
be maintained. The between-group differences on the earlier scan will be a secondary outcome. The 
primary analysis for this sub-study will use a similar method to the secondary clinical analysis of the 
main study (see section 6.2.1), and compare the ‘deltoid active’ AHD on coronal images between the 
debridement with InSpace device versus debridement alone groups using a t-test, and if possible, a 
generalised linear regression model adjusting for age, sex, tear size, and recruitment site.  
6.5.4 Effects of covid-19 on the sub-study 
As well as potentially having an impacting on participant recovery, the effects of the covid-19 
pandemic have limited recruitment and data collection for the sub-study. In particular, many MRI 
scans scheduled six months after randomisation have been delayed or cancelled due to limited staff 
capacity or participant safety considerations. Hence, the window to collect MRI scans to investigate 
longer term effects of the InSpace device has been extended. It is not anticipated that sufficient data 
will be collected to formally investigate temporal effects, however, plots of outcomes over time will 
be created to aid interpretation.  
6.6 Harms 
Safety monitoring will be conducted primarily through participant self-reporting. At each follow-up 
occasion, participants will be asked if they have had any adverse events and how these were 
managed. The relatedness, expectedness and severity of any serious adverse events (SAEs) will be 
summarised as displayed in Table 12 of the dummy tables. 
Complications deemed serious will be reported separately as SAEs. The number and nature will be 
reported and assessed by intervention arm, as shown in Table 12 of the dummy tables. 
6.7 Statistical software 
The routine statistical analysis will mainly be carried out using R [14] or Stata (e.g. StataCorp. 2019. 
Stata Statistical Software: College Station, TX: StataCorp LP). 
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8 Dummy tables 
The following tables fill form the basis for the final statistical report. For brevity, some tables which 
will be reported at multiple time points are shown once; with variables noted when reported where 
necessary. Note also that variable level missingness is not reported here, but will be marked in the 
final report as appropriate. 
Table 1: Participant flow from screening data 







Advanced Gleno-humeral OA  
Subscalpulus deficiency to be confirmed at surgery  
Interposition grafting or tendon transfers  
Pseudoparalysis  
Unrelated symptomatic ipsilateral shoulder pathology  
Unrelated neurological or muscular condition that would interfere 
with strength measurement or rehabilitation 
 
Previous proximal humerus fracture  
Previously entered trial  
Unable to complete trial procedures  
Age under 18  
Unable to consent to trial  
















Prefers conservative care/Does not want treatment   
Does not want to take part in research  
Does not want standard operation`  
Does not want InSpace device  
Does not like randomisation  
No reason given   
Other Other reason given  
 
Table 2: Participant flow from consented to randomisation. Values reported are numbers and percentages of number 
consented unless stated otherwise 
Reason not randomised n consented 
Excluded intra-operatively: Yes (n,%)  
Excluded intra-operatively: 
reason (n,%) 




Repairable cuff tear  
Other  
Withdrawn before surgery: Yes (n,%)  
Withdrawn before surgery: 
reason (n,%) 
No longer receiving surgery  
No longer wants to be part 
of the study 
 
Other  
No reason provided  
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North Bristol – Southmead    
North Tees    
Cambridge – Addenbrookes    
London North West    
Prince Philip    
Royal National Orthopaedic – Stanmore     
Royal Gwent Hospital    
Cardiff    
Royal Devon and Exeter    
Bournemouth    
Leicester    
Yeovil    
Guy’s and St Thomas’    
Salisbury    
West Suffolk    
Southampton    
Doncaster    
Wrexham    
Kingston    
Peterborough    
…    
Total    
 
 
Table 4: Summary of baseline data for randomised participants and participants excluded intra-operative. Values reported 
are means and standard deviations unless otherwise stated 






Constant score   
Shoulder free range of motion   
Forward flexion   
Abduction   
Age (n,%) 
<70 years   
≥70 years   
Sex (n,%) 
Male   
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Table 5: Summary of CRF completion (randomised participants) 









Complete    
Constant missing but data received    
CRFs missing    
6 weeks 
Complete    
Constant missing but data received    
Loss to follow up    
Withdrawn    
3 months 
Complete    
Constant missing but data received    
Lost to follow up    
Withdrawn    
6 months 
Complete    
Constant missing but data received    
Lost to follow up    
Withdrawn    
12 months 
Complete    
Constant missing but data received    
Lost to follow up    
Withdrawn    
24 months 
Complete    
Constant missing but CRFs returned    
Lost to follow up    
Withdrawn    
 





with device (n=) 
Total 
(n=) 
Age (years)    
Age group 70 years or older (n,%)    
Sex: Male (n,%)    
Shoulder entered into study: Left (n,%)    
Study shoulder participants’ dominant 
shoulder: Yes (n, %) 
   
Consented to MRI sub-study: Yes (n,%)    
Symptom duration (years/months)    
Left or right handed: Left (n,%)    
Current smoker: Yes (n,%)    
Diabetic: Yes (n,%)    
Diabetic - Type 1 or 2: Type 1 (n,%)    
Diabetic: 
Treatment (n,%) 
Insulin    
Medication    
Diet    
Other medical conditions: Yes (n,%)    
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History of dislocations: number of 
dislocations on same shoulder (n,%) 
  
 
History of dislocations: Time since 
last dislocation  
  
 
Unilateral or bilateral pain and 
symptoms: Unilateral (n,%) 
  
 
Previous physiotherapy: Yes (n,%)    
Steroid injection: Yes (n,%)    
Previous surgery: Yes (n,%)    
Other treatment: Yes (n,%)    
 










Antereo-Posterior size (cm)    




Biceps tendon intact: Yes (n,%)    
Subscapularis torn: Yes (n,%)    
Subscapularis 
torn 
Size of tear (cm)    
Repaired: Yes (n,%)    
Limited acromioplasty: Yes (n,%)    
CA ligament retained: Yes (n,%)    
Inspace device used: Yes (n, %)    
Size of device used 
(n, %) 
Small    
Medium    
Large    
Device was stable: Yes (n, %)    





Table 9: Patient reported outcome measures. Values reported are unadjusted means and standard deviations unless 
otherwise stated 










Baseline    
3 months    
6 months    
12 months    
Baseline    
   
 





3 months    
6 months    
12 months    
Forward 
flexion 
Baseline    
3 months    
6 months    
12 months    
Abduction 
Baseline    
3 months    
6 months    




Baseline    
3 months    
6 months    
12 months*    





Baseline    
3 months    
6 months    
12 months    
24 months    
EQ-5D 
Baseline    
3 months    
6 months    
12 months    




3 months    
6 months    
12 months    
24 months    
*Primary outcome 
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First MRI    




First MRI    




First MRI    
Final MRI    
 









All reported AEs (n)    
AEs per participant 
1    
2    
3    
4    
…    
Participant experienced any AE     
Additional surgery to study shoulder    
Additional injuries to study shoulder    
Injury to teeth mouth or throat during 
anaesthetic 
   
Chest infection    
Myocardial infection    
Nerve or vessel injury due to local anaesthetic    
Exacerbation/persistence of shoulder pain or 
restrictive range of motion 
   
Injection into the shoulder region    
Adhesive capsulitis    
Deep infection of the shoulder joint or implant     
Wound healing problems    
Thrombosis (DTV or PE)    
Damage to nerves or vessels in the surgical 
area 
   
Mis-placement of the device or its subsequent 
migration 
   
Device defect/failure    
Persistent muscle soreness or muscle injury    
Bruising    
Other    
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Table 12: Unexpected, related Serious Adverse Events (SAEs) 
*Unblinded assessment 
 









How is your shoulder 
now?  
Substantially Better    
Moderately Better    
No Different    
Moderately Worse    
Substantially Worse    
Global impression of 
change  
No change or worse    
Almost the same    
A little better    
Somewhat better    
Moderately better    
Better    
A great deal better    
Patient reported 
treatment group 
Arthroscopy only    
Arthroscopy with 
device 
   
Not sure    
 
 








All reported SAEs (n)    
SAEs per participant (n) 
1    
2    
…    
Life-threatening (n,% of SAEs in group)    
Hospitalisation or prolongation of existing 
hospitalisation (n, % of SAEs in group) 
   
Persistent or significant disability/incapacity (n,% of 
SAEs in group) 
   
Other reason  
(n, % of SAEs in group) 
   
Relatedness to intervention* (n, % of 
SAEs in group) 
Related    
Unrelated    
Potential relatedness to InSpace 
device only* (n, % of related SAEs in 
group) 
Related    
Unrelated    
If related, was the SAE expected (n, 
% of related SAEs in group) 
Expected    
Unexpected    
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Using any analgesia for shoulder: Yes    
Paracetamol 
Daily    
Up to weekly    
Up to monthly    
None    
Ibuprofen 
Daily    
Up to weekly    
Up to monthly    
None    
Codeine 
Daily    
Up to weekly    
Up to monthly    
None    
Co-codamol 
Daily    
Up to weekly    
Up to monthly    
None    
Tramadol 
Daily    
Up to weekly    
Up to monthly    
None    
… 
Daily    
Up to weekly    
Up to monthly    
None    
 
  
   
 
START: REACTS SAP Version 2 , 21 May 2021, Final Page 29 
 
9 List of abbreviations 
Abbreviation Explanation 
AE Adverse Event 
AHD Acromio-humeral distance 
CA Coraco-Acromial (a small ligament in the shoulder) 
Constant Constant Murley score 
CONSORT Consolidated Standards of Reporting Trials 
CRF Case Report Form 
CTU Clinical Trials Unit 
DMC Data Monitoring Committee 
ISRCTN International Standard Randomised Controlled Trial Number 
MCID Minimal Clinically Important Difference 
MRI Magnetic Resonance Imaging 
NICE The National Institute for Health and Care Excellence 
NIHR The National Institute for Health Research 
OSS Oxford Shoulder Score  
PPI Patient & Public Involvement 
PROMs Patient Reported Outcome Measures 
QoL Quality of Life 
QALY Quality Adjusted Life Year 
RCT Randomised Controlled Trial 
RDS Research Design Service 
REACTS Randomised, Efficient, Adaptive Clinical Trial in Surgery 
R&D Research and Development 
SAE Serious Adverse Event 
SOP Standard Operating Procedure 
START Subacromial spacer for Tears Affecting Rotator cuff Tendons (Study title) 
TMG Trial Management Group 
TSC Trial Steering Committee 
VAS Visual Analogue Scale 
WCTU Warwick Clinical Trials Unit 
WORC Western Ontario Rotator Cuff 
 
 
